Abstract
Purpose
Because it is unknown whether adjusting the dose of sunitinib can benefit patients with pancreatic neuroendocrine neoplasms (Pan-NENs), this retrospective study examined maximum tumor shrinkage rates and prognoses in patients with and without low doses of sunitinib administration.
Methods
Eighty-seven patients with metastatic and unresectable neoplasms, treated with sunitinib for > 1 month, were divided into a low-dose (LD) or high-dose (HD) group. The tumor response rates were investigated over time using computed tomography according to the response evaluation criteria in solid tumors criteria.
Results
The LD and HD groups included 42 and 45 patients, respectively. There were no differences in baseline characteristics (tumor size, Ki-67 index, mitosis, and differentiation) between the two groups. Progressive disease (PD), stable disease (SD), and partial response (PR) were observed in 16.7, 54.8, and 28.6% of patients in the LD group, respectively, and in 13.3, 60, and 26.7% of patients in the HD group, respectively. There were no differences in tumor shrinkage rates between the two groups (p = 0.87). The 3-year progression-free survival rates for the LD and HD groups were 2.4% and 2.3%, respectively (p = 0.67), and the 3-year overall survival rates were 57.9% and 70.5%, respectively (p = 0.76). The occurrence of adverse events was similar between the two groups (61.9% vs. 60.0%, p > 0.95).
Conclusions
Dose reduction of sunitinib did not alter tumor shrinkage rates or prognoses for patients with advanced Pan-NENs.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
References
Abrams TJ, Lee LB, Murray LJ, Pryer NK, Cherrington JM (2003) SU11248 inhibits KIT and platelet-derived growth factor receptor beta in preclinical models of human small cell lung cancer. Mol Cancer Therap 2:471–478
Boegemann M, Hubbe M, Thomaidou D, Blackburn S, Bent-Ennakhil N, Wood R, Bargo D (2018) Sunitinib treatment modification in first-line metastatic renal cell carcinoma: analysis of the STAR-TOR registry. Anticancer Res 38:6413–6422. https://doi.org/10.21873/anticanres.13002
Casanovas O, Hicklin DJ, Bergers G, Hanahan D (2005) Drug resistance by evasion of antiangiogenic targeting of VEGF signaling in late-stage pancreatic islet tumors. Cancer Cell 8:299–309. https://doi.org/10.1016/j.ccr.2005.09.005
Faivre S et al (2017) Sunitinib in pancreatic neuroendocrine tumors: updated progression-free survival and final overall survival from a phase III randomized study. Ann Oncol 28:339–343. https://doi.org/10.1093/annonc/mdw561
Fjallskog ML, Lejonklou MH, Oberg KE, Eriksson BK, Janson ET (2003) Expression of molecular targets for tyrosine kinase receptor antagonists in malignant endocrine pancreatic tumors. Clin Cancer Res 9:1469–1473
Houk BE, Bello CL, Poland B, Rosen LS, Demetri GD, Motzer RJ (2010) Relationship between exposure to sunitinib and efficacy and tolerability endpoints in patients with cancer: results of a pharmacokinetic/pharmacodynamic meta-analysis. Cancer Chemotherap Pharmacol 66:357–371. https://doi.org/10.1007/s00280-009-1170-y
Ito T et al (2013) Phase II study of sunitinib in Japanese patients with unresectable or metastatic, well-differentiated pancreatic neuroendocrine tumor. Investig New Drugs 31:1265–1274. https://doi.org/10.1007/s10637-012-9910-y
Ito T et al (2015) Epidemiological trends of pancreatic and gastrointestinal neuroendocrine tumors in Japan: a nationwide survey analysis. J Gastroenterol 50:58–64. https://doi.org/10.1007/s00535-014-0934-2
Mendel DB et al (2003) In vivo antitumor activity of SU11248, a novel tyrosine kinase inhibitor targeting vascular endothelial growth factor and platelet-derived growth factor receptors: determination of a pharmacokinetic/pharmacodynamic relationship. Clin Cancer Res 9:327–337
Mizuno Y et al (2018) Sunitinib shrinks NET-G3 pancreatic neuroendocrine neoplasms. J Cancer Res Clin Oncol 144:1155–1163. https://doi.org/10.1007/s00432-018-2636-2
Motzer RJ et al (2007) Sunitinib versus interferon alfa in metastatic renal-cell carcinoma. New Engl J Med 356:115–124. https://doi.org/10.1056/NEJMoa065044
Motzer RJ et al (2013) Pazopanib versus sunitinib in metastatic renal-cell carcinoma. New Engl J Med 369:722–731. https://doi.org/10.1056/NEJMoa1303989
Murray LJ et al (2003) SU11248 inhibits tumor growth and CSF-1R-dependent osteolysis in an experimental breast cancer bone metastasis model. Clin Exp Metastasis 20:757–766
Pape UF, Bohmig M, Berndt U, Tiling N, Wiedenmann B, Plockinger U (2004) Survival and clinical outcome of patients with neuroendocrine tumors of the gastroenteropancreatic tract in a german referral center. Ann N Y Acad Sci 1014:222–233
Pavel M et al (2016) ENETS consensus guidelines update for the management of distant metastatic disease of intestinal, pancreatic, bronchial neuroendocrine neoplasms (NEN) and NEN of unknown primary site. Neuroendocrinology 103:172–185. https://doi.org/10.1159/000443167
Raymond E et al (2011) Sunitinib malate for the treatment of pancreatic neuroendocrine tumors. New Engl J Med 364:501–513. https://doi.org/10.1056/NEJMoa1003825
Vazquez S, Leon L, Fernandez O, Lazaro M, Grande E, Aparicio L (2012) Sunitinib: the first to arrive at first-line metastatic renal cell carcinoma. Adv Therap 29:202–217. https://doi.org/10.1007/s12325-011-0099-9
Wang Y et al (2017) Sunitinib is effective and tolerable in Chinese patients with advanced pancreatic neuroendocrine tumors: a multicenter retrospective study in China. Cancer Chemother Pharmacol 80:507–516. https://doi.org/10.1007/s00280-017-3367-9
Yao JC et al (2008) One hundred years after “carcinoid”: epidemiology of and prognostic factors for neuroendocrine tumors in 35,825 cases in the United States. J Clin Oncol 26:3063–3072. https://doi.org/10.1200/jco.2007.15.4377
Yoo C et al (2017) Efficacy and safety of everolimus and sunitinib in patients with gastroenteropancreatic neuroendocrine tumor. Cancer Chemother Pharmacol 79:139–146. https://doi.org/10.1007/s00280-016-3215-3
Acknowledgements
All pathological diagnoses were revised by Yuko Kinowaki at Department of human Pathology, Graduate school of Medicine, Tokyo Medical and Dental University.
Funding
This work was supported by Grant-in-Aid for Scientific Research (C) Grant Number 19K09041.
Author information
Authors and Affiliations
Contributions
Study concept and design: SM. Analysis and interpretation of data: SM, AK. Acquisition of data: SM, AK, TO, KO, HO, YM, DB. Drafting of the manuscript: SM, AK. Critical revision of the manuscript for important intellectual content: ST. Statistical analysis: SM. Obtained funding: AK. Administrative, technical, or material support; AK. Study supervision: MT.
Corresponding author
Ethics declarations
Conflict of interest
The authors declare that they have no conflict of interest.
Additional information
Publisher's Note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
About this article
Cite this article
Matsui, S., Kudo, A., Ogura, T. et al. Does sunitinib have a patient-specific dose without diminishing its antitumor effect on advanced pancreatic neuroendocrine neoplasms?. J Cancer Res Clin Oncol 145, 2097–2104 (2019). https://doi.org/10.1007/s00432-019-02947-7
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00432-019-02947-7